Use of carbamate compound for preventing, alleviating or treating myotonia
The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating myotonia.
1. A method for alleviating or treating myotonia, comprising administering to a subject in need thereof a therapeutically effective amount of a carbamate compound which is carbamic acid (R)-1-(2-chlorophenyl)-2-tetrazol-2-yl)ethyl ester of the following Formula 2, or a pharmaceutically acceptable salt, solvate or hydrate thereof:
2. The method according to claim 1 , wherein a disease which represents myotonia is at least one selected from myotonic dystrophy, myotonia congenita and paramyotonia congenita.
3. The method according to claim 1 , wherein myotonia has a sporadic etiology.
4. The method according to claim 1 , wherein myotonia has a hereditary etiology with a family history.
5. The method according to claim 2 , wherein myotonic dystrophy is DM type 1 or DM type 2.
6. The method according to claim 2 , wherein myotonia congenita is Becker's disease or Thomsen's disease.
7. The method according to claim 1 , wherein the subject to be administered is a mammal.
8. The method according to claim 1 , wherein the therapeutically effective amount of the carbamate compound of Formula 2 is 50 to 500 mg based on the free form when administered once a day.